Manus B, Brägelmann R, Armbrecht U, Stolte M, Stockbrügger R W
Marbachtalklinik, Bad Kissingen, Germany.
Eur J Cancer Prev. 1996 Feb;5(1):49-55.
Mortality from colorectal cancer (CRC) can be reduced by screening of asymptomatic individuals and by removal of colorectal adenomas (CRA). It is still under debate which screening method should be used. In a clinical rehabilitation centre we compared two widely different approaches: faecal occult blood testing (FOBT) with subsequent endoscopy of test-positives in an unselected patient group, and primary sigmoidoscopy of asymptomatic persons between 50 and 60 years of age. Between January 1988 and October 1991 a FOBT was offered to all--symptomatic and asymptomatic--6,500 in-patients of a clinical rehabilitation centre and lower/upper GI-endoscopy was suggested to test-positives (study A). In the latter half of this period 1,166 persons without bowel symptoms and/or disease and aged 50-60 years were invited to a screening sigmoidoscopy (study B). In study A 95% of the patients (n = 6,234) returned a complete FOBT, which was positive in 186 (2.98%). 126 of these 186 patients (68%) accepted further investigation, and a total of 78 sigmoidoscopies, 78 colonoscopies and 47 gastroscopies were performed. Six patients in whom a malignancy was detected (1 gastric, 1 rectal and 4 colonic; all in a curable stage) underwent surgery. In 28 patients CRA were identified and removed by snare excision. In study B 658/1,166 asymptomatic in-patients accepted the screening sigmoidoscopy (56%). Rectosigmoid adenomas were identified in 153 (23%). One rectal cancer was found. Of these cases, 116 underwent an additional colonoscopy, disclosing proximal adenomas in 39 patients (33.6%). The cost of identifying one CRA-bearer was $1,436 in study A and $271 in study B (assuming: FOBT = $3.00; sigmoidoscopy = $63.00; colonoscopy = $135; gastroscopy = $108). In study A, the cost of identifying one patient with cancer would have been $5,435, if the cost of identifying one CRA-bearer was set to $271 as in study B. Screening for CRC was well-accepted in the health-orientated environment of a rehabilitation centre. The cost of identifying a CRA-bearer with screening sigmoidoscopy was about one-fifth of that using preselection with a FOBT. However, with FOBT a higher number of cancers was found. For the discovery of CRA, mass-screening with sigmoidoscopy of persons above the age of 50 years can be advised. For the detection of both CRA and CRC, screening with FOBT and subsequent endoscopy is an acceptable and cost-effective method.
通过对无症状个体进行筛查以及切除大肠腺瘤(CRA),可降低结直肠癌(CRC)的死亡率。究竟应采用哪种筛查方法仍存在争议。在一家临床康复中心,我们比较了两种截然不同的方法:对未经过挑选的患者群体进行粪便潜血试验(FOBT),随后对检测呈阳性者进行内镜检查;以及对50至60岁的无症状者进行乙状结肠镜检查。1988年1月至1991年10月期间,对一家临床康复中心的6500名住院患者(包括有症状和无症状的)均进行了FOBT,并建议检测呈阳性者接受上下消化道内镜检查(研究A)。在此期间的后半段,邀请了1166名无肠道症状和/或疾病且年龄在50至60岁的人接受筛查乙状结肠镜检查(研究B)。在研究A中,95%的患者(n = 6234)完成了完整的FOBT,其中186例(2.98%)呈阳性。这186例患者中有126例(68%)接受了进一步检查,共进行了78次乙状结肠镜检查、78次结肠镜检查和47次胃镜检查。检测出6例恶性肿瘤患者(1例胃癌、1例直肠癌和4例结肠癌;均处于可治愈阶段)并接受了手术。28例患者经圈套切除术识别并切除了CRA。在研究B中,658/1166例无症状住院患者接受了筛查乙状结肠镜检查(56%)。发现直肠乙状结肠腺瘤153例(23%)。发现1例直肠癌。在这些病例中,116例患者还接受了结肠镜检查,其中39例患者(33.6%)发现了近端腺瘤。在研究A中,识别一名携带CRA者的成本为1436美元,在研究B中为271美元(假设:FOBT = 3美元;乙状结肠镜检查 = 63美元;结肠镜检查 = 135美元;胃镜检查 = 108美元)。在研究A中,如果像研究B那样将识别一名携带CRA者的成本设定为271美元,那么识别一名癌症患者的成本将为5435美元。在康复中心这种注重健康的环境中,CRC筛查很容易被接受。通过筛查乙状结肠镜检查识别一名携带CRA者的成本约为采用FOBT预筛选的五分之一。然而,通过FOBT发现的癌症数量更多。对于发现CRA,建议对50岁以上人群进行乙状结肠镜大规模筛查。对于同时检测CRA和CRC,采用FOBT及随后的内镜检查是一种可接受且具有成本效益的方法。